• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MBRX

    Moleculin Biotech Inc.

    Subscribe to $MBRX
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: moleculin.com

    Peers

    $AUPH
    $BBI
    $KRYS
    $ONCY
    $PMCB

    Recent Analyst Ratings for Moleculin Biotech Inc.

    DatePrice TargetRatingAnalyst
    2/12/2025Buy → Hold
    Maxim Group
    7/18/2022$14.00Outperform
    Oppenheimer
    See more ratings

    Moleculin Biotech Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Moleculin Biotech downgraded by Maxim Group

      Maxim Group downgraded Moleculin Biotech from Buy to Hold

      2/12/25 8:44:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Moleculin Biotech with a new price target

      Oppenheimer resumed coverage of Moleculin Biotech with a rating of Outperform and set a new price target of $14.00

      7/18/22 9:16:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Moleculin Biotech

      Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy

      2/1/21 4:03:54 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Moleculin Biotech with a new price target

      Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $29.00 from $5.00 previously

      2/1/21 11:22:36 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      11/14/24 5:12:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Moleculin Biotech Inc.

      SC 13G - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/14/24 3:43:13 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/10/21 11:28:21 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Financials

    Live finance-specific insights

    See more
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported its financial results

      3/24/25 7:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing t

      3/19/25 8:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      - On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R/R AML in Q1 2025 - Median durability of CRc in MB-106 Annamycin+ Cytarabine AML clinical trial continues to climb - now past 8 months  - Recent virtual AML KOL event underscores how Annamycin could significantly change the AML treatment landscape; Replay available here  - Company to host conference call and webcast today, Monday, November 11th at 8:30 AM ET HOUSTON, Nov. 11, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical

      11/11/24 7:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

      HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended September 30, 2024, on Friday, November 8, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, November 11, 2024. Interested participants and investors may access the confe

      11/5/24 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

      Live webcast discussion featuring internationally renowned Acute Myeloid Leukemia (AML) Key Opinion Leaders Ongoing progress of pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML HOUSTON, Oct. 7, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it will host a Virtual Acute Myeloid Leukemia KOL event on Monday, October 14th from 11:00 AM – 1:00 PM ET.

      10/7/24 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

      HOUSTON, Aug. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it will host a corporate update webcast presentation on Tuesday, August 6, 2024 at 8:30 AM ET to discuss its recently announced plans to advance Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 "MIRACLE"

      8/5/24 9:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

      –     Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) –     Also announced MB-106 reaches 20 subjects enrolled –     Company to host conference call and webcast today, Monday, May 13th at 8:30 AM ET HOUSTON, May 13, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the quarter ended March 31, 2024. As previously announced, the Company will

      5/13/24 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

      HOUSTON, May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended March 31, 2024, on Friday, May 10, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13, 2024. Interested participants and investors may access the conference call

      5/8/24 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

      –     Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects –     AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line therapies –     All 82 Annamycin subjects (in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy –     Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway –     Company to host conference call and webcast today, March 25th at 8:30 AM ET HOUSTON, March 25, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (

      3/25/24 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yan Joy

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:06:10 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cermak Elizabeth

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:05:23 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Climaco John M

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:04:49 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director George Robert E.

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:03:56 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Science Officer Picker Donald H

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:03:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cannon Michael D

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:03:07 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Foster Jonathan P.

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:00:49 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Klemp Walter V

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:00:17 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Klemp Walter V converted options into 982 shares and covered exercise/tax liability with 240 shares, increasing direct ownership by 1% to 57,035 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      7/5/24 5:01:18 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Science Officer Picker Donald H converted options into 1,766 shares, increasing direct ownership by 18% to 8,001 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      6/25/24 6:02:39 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin

      Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin for the treatment of acute myeloid leukemia (AML); Interim data readout expected in the second half of 2025 HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organizat

      5/6/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

      Company continues to expand global IP coverage and claims to major markets, now extending to June 2040  HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with claims covering Annamycin. U.S. patent number 12,257,261 titled, "Preparation of Preliposomal Annamycin Lyophilizate", has claims covering methods of making liposomal Annamycin and U.S. patent 12,257,262 titled "Method of Reconstituting Liposomal Anna

      5/5/25 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

      Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that an abstract and poster presentation regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association f

      4/29/25 8:35:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

      HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. Details of the presentation are as follows: Title: Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabi

      4/17/25 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

      – Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnA

      4/1/25 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported its financial results

      3/24/25 7:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing t

      3/19/25 8:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

      On-demand video webcast now available here HOUSTON, March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Mole

      3/11/25 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Present at the 37th Annual ROTH Conference

      Live webcast fireside chat on Tuesday, March 18th at 11:00 AM PT HOUSTON, March 10, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in a fireside chat on Tuesday, March 18, 2025 at 11:00 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA. In addition to the presentation, management will be available

      3/10/25 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. SEC Filings

    See more
    • Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/9/25 5:00:27 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/7/25 9:00:33 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/6/25 9:00:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/5/25 8:45:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Moleculin Biotech Inc.

      10-K/A - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/30/25 4:36:43 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/29/25 8:35:09 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Other Events

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/25/25 5:00:30 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/21/25 4:42:40 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Moleculin Biotech Inc.

      10-K/A - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/18/25 4:31:08 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      4/17/25 8:35:19 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:32:37 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:57 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:05 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Moleculin Biotech Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

      Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the appointment of Daniel D. Von Hoff, M.D., F.A.C.P., FASCO, FAACR to its Annamycin Scientific Advisory Board. Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We are very pleased to welco

      11/4/24 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

      Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to dateOngoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathwayHOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinica

      5/2/24 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

      –     Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman. Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-

      5/1/24 8:50:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023

      - Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so   HOUSTON, May 30, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that its annual meeting of stockholders (the "Annual Meeting") scheduled for and convened on Thursday, May 25, 2023 has been partially adjourned to Thursday, June 15, 2023 at 10:30 a.m. Eastern Time.

      5/30/23 9:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

      HOUSTON, March 1, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the appointment of Joy Yan, M.D., Ph.D. to its Board of Directors. "We are incredibly pleased to welcome Dr. Yan to our Board of Directors. Her leadership and expertise in building, executing, and advancing clinical programs with major players in the pharma industry will be a valuable perspective as we work to progress our po

      3/1/22 8:35:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care